All In Biotech

Drug Trial Radar · NCT00907803

Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Assess Safety, Tolerability, and PK of the Anti-Orthopoxvirus Compound ST-246 When Administered as a Single Daily Oral Dose for 14 Days in Volunteers in the Fed State

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Jun 2009

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
SIGA TechnologiesIndustry
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH)
First posted
May 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.

Conditions

  • Orthopoxviral Disease

Interventions

  • ST-246 400 mgDrug

    Capsules, 400 mg daily for 14 days

  • ST-246 600 mgDrug

    Capsules, 600 mg daily for 14 days

  • PlaceboDrug

    Capsules, once daily for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Study Participants Who Tolerated a Single Daily Oral ST-246 Dose as Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.Time frame: Days 1 to 14; then 24, 48, 72, 96 and 120 hours and 4 weeks after final dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Apex Research Institute

    Santa Ana, California

  • Orlando Clinical Research Center

    Orlando, Florida

  • Hawaii Clinical Research Center

    Honolulu, Hawaii

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.